Asian-focused outcomes with first-line (1L) obrixtamig plus standard of care (SoC) in pts with DLL3-positive extrapulmonary neuroendocrine carcinoma (epNEC): Phase Ib DAREON®-7 study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #664P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • P1 data • Endocrine Cancer • Neuroendocrine Carcinoma • Oncology • Solid Tumor • DLL3
|
|
Saori Mishima; Aman Chauhan; Ana Custodio; Emmanuel Mitry; Rocio Garcia-Carbonero; Janie Y. Zhang; Ken Kato; Julia Koevi; Svenja Maria Palm; Zilu Liu; Valeria Lifke; Timon Vandamme; Jaume Capdevila
|